Tissue Regenix Group PLC Exercise of Options and Total Voting Rights (9962K)
31 Agosto 2023 - 3:05PM
UK Regulatory
TIDMTRX
RNS Number : 9962K
Tissue Regenix Group PLC
31 August 2023
Tissue Regenix Group plc
('Tissue Regenix', the 'Company' or the 'Group')
Exercise of Options
And Total Voting Rights
Tissue Regenix Group (AIM:TRX), the regenerative medical devices
company, announces that it has received notification for the
exercise of options to subscribe for 216,519 new ordinary shares in
the Company ("Ordinary Shares") at an exercise price of 27.6 pence
per Ordinary Share. These shares are being issued pursuant to an
exercise of options under the 2020 Tissue Regenix Group plc SAYE
Option Plan.
The above number includes 65,217 Ordinary Shares issued to
Kirsten Lund, a PDMR of the Company. Following the issue, Kirsten
will hold 65,217 Ordinary Shares, representing 0.09% of the
Company's issued share capital.
The 216,519 new Ordinary Shares will rank pari passu with the
existing Ordinary Shares and application has been made for these
new Ordinary Shares to be admitted to trading on AIM. It is
expected that admission will occur at 8:00 a.m. on 6 September
2023.
Total Voting Rights
Following the issue of the 216,519 new Ordinary Shares, the
Company will have a total of 70,574,468 Ordinary Shares in issue.
The above figure may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change in their
interest in, the share capital of the Company under the FCA's
Disclosure and Transparency Rules.
For more information:
Tissue Regenix Group plc www.tissueregenix.com
Daniel Lee, Chief Executive Officer Via Walbrook PR
finnCap Ltd (Nominated Adviser and Broker)
Emily Watts/Geoff Nash/George Dollemore -
Corporate Finance
Nigel Birks/Harriet Ward - ECM
Walbrook PR (Financial PR & IR) Tel: +44(0)20 7933 8780
Alice Woodings/Lianne Applegarth TissueRegenix@walbrookpr.com
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in the field
of regenerative medicine. The Company's patented decellularisation
technology ('dCELL(R)') removes DNA and other cellular material
from animal and human soft tissue, leaving an acellular tissue
scaffold that is not rejected by the patient's body and can then be
used to repair diseased or damaged body structures. Current
applications address many critical clinical needs in sports
medicine, foot and ankle and wound care.
In August 2017, Tissue Regenix acquired CellRight
Technologies(R), a biotech company that specialises in regenerative
medicine and is dedicated to the development of high-quality,
innovative tissue scaffolds, which can enhance healing
opportunities in defects created by trauma and disease. CellRight's
human tissue products may be used in spine, trauma, general
orthopaedic, dental and ophthalmological surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOESDMFEFEDSEDA
(END) Dow Jones Newswires
August 31, 2023 08:45 ET (12:45 GMT)
Tissue Regenix (LSE:TRX)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Tissue Regenix (LSE:TRX)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024